Fortitude Biomedicines

Executive Summary

Fortitude Biomedicines is a private, preclinical-stage biotechnology company pioneering next-generation antibody-drug conjugates (ADCs) using its proprietary GLUE-DAC™ platform. The platform uniquely employs molecular glue degraders as therapeutic payloads, enabling precise targeting of disease-associated proteins while minimizing off-target effects and overcoming resistance mechanisms common in autoimmune diseases and cancer. Founded in 2021 and based in Cambridge, MA, the company operates in stealth mode with no disclosed funding or pipeline details. Its differentiated approach positions it to address significant unmet needs in oncology and immunology, though it remains at a very early stage with substantial technical and clinical risks. The successful demonstration of preclinical proof-of-concept and advancement toward IND-enabling studies will be critical for attracting further investment and partnerships.

Upcoming Catalysts (preview)

• Q4 2026Presentation of preclinical proof-of-concept data for lead ADC program50% success
• Q1 2027Series A financing round to fund IND-enabling studies60% success
• Q2 2027Announcement of strategic partnership or licensing deal for GLUE-DAC platform30% success